Open AccessChallenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue
Author(s) -
Stroh M,
Carlile DJ,
Li CC,
Wagg J,
Ribba B,
Ramanujan S,
Jin J,
Xu J,
Charoin JE,
Xhu ZX,
Morcos PN,
Davis JD,
Phipps A
Publication year - 2015
Publication title -
cpt: pharmacometrics and systems pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 37
ISSN - 2163-8306
DOI - 10.1002/psp4.12014
Subject(s) - cancer immunotherapy , immunotherapy , clinical pharmacology , immune system , cancer treatment , cancer , medicine , pharmacology , immunology
Cancer immunotherapy (CIT) initiates or enhances the host immune response against cancer. Following decades of development, patients with previously few therapeutic options may now benefit from CIT. Although the quantitative clinical pharmacology (qCP) of previous classes of anticancer drugs has matured during this time, application to CIT may not be straightforward since CIT acts via the immune system. Here we discuss where qCP approaches might best borrow or start anew for CIT.